anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a blood circulation promoting soft ginseng-leech capsule for treating coronary diseases and angina pectoris and a method for preparing the soft ginseng-leech capsule. The present invention is characterized in that the soft ginseng-leech capsule is prepared from raw materials, in weight percentages, 10 to 60% of red ginseng, 15 to 70% of chuanxiong rhizome, 10 to 45% of leech, 0.5 to 10% of storax and 0.1 to 3% of borneol. The medicine is prepared on the basis of the treating methods of benefiting qi, removing blood stasis, promoting blood circulation and alleviating pain. The blood circulation promoting soft ginseng-leech capsule not only can strengthen the heat, restore pulses and invigorate insufficiency of the heart and qi to treat root causes, but also can activate blood circulation and dissipate blood stasis to remove symptoms. If angina pectoris attacks, the shell of the soft capsule can be bitten for sublingual administration to obtain quick action, and the soft capsule can also be taken for a long term without affecting body resistance. As a result, the present invention has the effects of restoring qi deficiency, removing static blood, promoting blood circulation to alleviate pain, and treating both root causes and symptoms.
PURPOSE: To review the composition, preparation, proposed mechanism of action, safety, efficacy, and current place in therapy of Rebyota (fecal microbiota, live-jslm).
SUMMARY: As the first agent in a new class of drugs, live biotherapeutic products (LBPs), fecal microbiota, live-jslm offers another therapeutic approach for the prevention of recurrent Clostridioides difficile infection (rCDI). LBPs are given following antibiotic therapy for C. difficile to reintroduce certain bacteria present in the normal microbiome, as a means to reconstitute the microbiome of infected individuals. This review provides a summary of phase 2 and 3 clinical trials, product information, discussion of data limitations, and recommendations for place in therapy. High efficacy rates compared to placebo with sustained response up to 24 months after administration have been reported. The majority of adverse events identified were mild to moderate without significant safety signals.
CONCLUSION: Fecal microbiota, live-jslm has consistently been shown in randomized trials to be safe and effective in reducing rCDI. Its approval marks the culmination of decades of work to identify, characterize, and refine the intestinal microbiome to create pharmaceutical products.
Patients receive FDG IV and undergo FDG PET/CT scan over 20-30 minutes if they have not already had one per standard of care. At least 20-24 hours later, patients receive fluorine F 18 fluorthanatrace IV and undergo \[18F\]FTT PET/CT over 1 hour.
All patients will receive radiation therapy scheme: 41.4Gy in 23 fractions over 5 weeks, concurrently with 5 cycles of paclitaxel/cisplatin (paclitaxel 45mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22,29 and 2 cycles of toripalimab 240 mg every 3 weeks after chemoradiotherapy. Esophagectomy is performed 6-8 weeks after CRT completion and after operation patients received 4 cycles of toripalimab 240 mg every 3 weeks for adjuvant treatment.
PROBLEM TO BE SOLVED: To obtain a thiol protease inhibitor containing a specific vitamin as an active component and useful as an agent for the treatment of osteoporosis and hypercalcemia, an antiallergic agent, etc. SOLUTION: This agent contains a vitamin B6 as an active component. The vitamin B6 is especially preferably pyridoxal, pyridoxalphosphoric acid or pyridoxamine. The thiol protease inhibitor is useful as an agent for the treatment of muscular dystrophy, amyotrophy, myocardial infarction, cerebral apoplexy, Alzheimers disease, consciousness disorder and movement disorder in head injury, disseminated sclerosis, neuropathy of peripheral nerve, cataract, inflammation, allergy, fulminant hepatitis, breast carcinoma, prostatic carcinoma, prostatic hypertropy, etc. It is also useful as an agent for suppressing the proliferation of cancer cell, preventing the metastasis of cancer, inhibiting the coagulation of platelet, etc. The administration rate of the active component is about 0.1-100mg/kg/day, preferably about 0.5-50mg/kg/day.
A 6-month-old girl, previously diagnosed with cystic fibrosis (CF), was admitted to hospital for nephrolithiasis. Her parents were first-degree cousins. The patient underwent endoscopic stone management. Despite no family history of stones and medical treatment with potassium citrate, the patient developed recurrent renal stones and atypical urinary tract infections during follow-up. Basic investigations were all normal. Due to consanguinity and early presentation of nephrolithiasis, metabolic causes such as cystinuria and hyperoxaluria were considered. Cystinuria was excluded due to normal cystine levels. High urinary oxalate excretion was found as expected due to absorptive (secondary) hyperoxaluria in CF patients. An early stone burden in the patient with a history of medical treatment and consanguinity led us to perform a genetic testing. Genetic testing revealed a missense homozygous variant in exon 1 of the AGXT gene. The patient was diagnosed with primary hyperoxaluria type 1. Two rare life-threatening genetic diseases were found together in the same child.
The genetic basis of schizophrenia (SZ) remains elusive despite its characterization as a highly heritable disorder. This incomplete understanding has led to stagnation in therapeutics and treatment, leaving many suffering with insufficient relief from symptoms. However, recent large-cohort genome- and exome-wide association studies have provided insights into the underlying genetic machinery. The scale of these studies allows for the identification of ultra-rare mutations that confer substantial disease risk, guiding clinicians and researchers toward general classes of genes that are central to SZ etiology. One such large-scale collaboration effort by the Schizophrenia Exome Sequencing Meta-Analysis consortium identified ten, high-risk, ultra-rare, protein-truncating variants, providing the clearest picture to date of the dysfunctional gene products that substantially increase risk for SZ. While genetic studies of SZ provide valuable information regarding "what" genes are linked with the disorder, it is an open question as to "when" during brain development these genetic mutations impose deleterious effects. To shed light on this unresolved aspect of SZ etiology, we queried the BrainSpan developmental mRNA expression database for these ten high-risk genes and discovered three general expression trajectories throughout pre- and postnatal brain development. The elusiveness of SZ etiology, we infer, is not only borne out of the genetic heterogeneity across clinical cases, but also in our incomplete understanding of how genetic mutations perturb neurodevelopment during multiple critical periods. We contextualize this notion within the National Institute of Mental Health's Research Domain Criteria framework and emphasize the utility of considering both genetic variables and developmental context in future studies.
A method and system for non-vascular sensor implantation. An implant unit is implanted in an area of a body and a foreign body capsule is allowed to form around the area of the implant unit. The sensor may be directed into a body cavity such as, for example, the peritoneal space, subcutaneous tissues, the foreign body capsule, or other area of the body. A subcutaneous area of the body may be tunneled to place the sensor. The system may include an implant unit such as, for example, for delivering drug to a human body and a sensor for detecting a physiological parameter. The sensor may be separate from and connectable to the implant unit and may be placed in a non-vascular area of the human body.
PURPOSE:To provide a plaster for an adhesive salve preparation preservable for a long period, by compounding one or more substances selected from pyridoxine, pyridoxine ester and their salts to a plaster composed of an adhesive substance. CONSTITUTION:A plaster composed of an adhesive substance such as rubber- based adhesive substance (e.g. natural rubber, synthetic rubber, etc.) is compounded with 0.002-10wt%, preferably 0.01-5wt%, based on the whole plaster, of pyridoxine, a pyridoxine ester (preferably a fatty acid ester such as caprylate, caprinate, laurate, etc.) or their salts. When a dermatic drug is compounded to the plaster, a stable adhesive plaster preparation free from the decomposition of the drug component can be obtained. The composition is especially effective when the drug is a compound containing phenolic hydroxyl group or an amino compound.
The present invention relates to drinking liquid having a nutritive value and a disease treating effect without any side effect on a human body, particularly to nutritive liquid for preserving vigour. The nutritive liquid is processed from a plurality of medicinal materials, such as white tuckahoe, red date, walnut meat, honey, etc., through processes, such as decoction, etc. The nutritive liquid rich in calcium, ferrum, vitamins, amino acid, etc. performs the functions of human body immunity enhancement and human body system regulation without any side effect on a human body, and the nutritive liquid has obvious therapeutic effects on the treatment of neurasthenia, insomnia, amnesia, etc. The nutritive liquid has obvious therapeutic effects on the treatment of certain monoscience diseases, such as anemia, cardiovascular diseases, lymphangitis, infertility, or even on white hair blackening, regeneration of shed teeth, etc. if the proportions of part of the medicines are appropriately adjusted.
Prostate cancer (PCa) is the second most common cancer among men in the United States, with over 180,000 new cases diagnosed in 2016. This commonality implies that set standards need to be set and devise effective tools to screen and diagnose prostate cancer. Today, prostate specific antigen (PSA) test is the most widely adopted screening method for PCa. Since its introduction in 1979, it has helped in earlier diagnosis of PCa and has had a marked shift on the stage at which PCa is identified. PSA, although popular as a screening tool, has several shortcomings. It is organ-specific rather than cancer-specific, which means that its values can be elevated even for non-malignant conditions . Indeed, PSA based screening has reported positive predictive value as low as 30% (PSA cutoff \>4.0 ng/dL) for detecting prostate cancer and an over diagnosis rate of 50%, which leads to unnecessary biopsies and aggressive treatments of men with clinically indolent (insignificant) disease.

Current diagnostic pathway of prostate cancer requires men with elevated PSA and abnormal Digital Rectal exam to undergo a Trans Rectal Ultra Sound (TRUS) guided biopsy. TRUS is a blind-systematic biopsy, which randomly samples prostate tissue. This can lead to missing or under-diagnosing clinically significant cancer and over-diagnosing clinically insignificant disease. TRUS biopsy is itself associated with morbidity, mainly in the form of hematuria, hematospermia, pain, urinary retention and sometimes can cause life-threatening sepsis.

Many of the PSA screened detected prostate cancers detected on TRUS are clinically insignificant and even if left untreated have little to no clinical impact on an individual's remaining life. Overtreatment resulting from over diagnosis often leads to side effects like erectile dysfunction (approx. 60%) from radical therapy and urinary incontinence.
Fixing permed human hair (which has been (i) treated with at least one perming compsn. (contg. at least one reducing agent) which has a pH of 6.5-8.0; and (ii) rinsed) comprises treating the hair with a compsn; comprising 1.5-5 wt. % of H202 and having a pH of 6.5-7.5. The compsn. is claimed per se. USE/ADVANTAGE - The compsn. gives improved fixing compared to prior art fixing compsns
Buoyant oral therapeutic dosage forms include at least one structural element with hollow cavities. Specifically the structural element may be a foamed or microporous polymer matrix, e.g. of polyolefin, polyamide, polyester, polystyrene, polyacrylate, PTFE, PVC, polyvinylidene chloride or polysiloxane, e.g in the form of a foldable or rollable film or a tablet core or layer. Alternatively, the structural elements may be hollow particles, e.g. of glass or ceramics, incorporated in a drug-contg. matrix (esp. hydrogel) or coated with a drug-contg. compsn. esp. for use in capsules). The dosage forms may be provided with a release-controlling membrane.
Single arm, interventional. All participants will be contacted over the phone to answer questions from a COVID-19 vaccine hesitancy and acceptance survey.
Snakebite envenomation is a major public health issue which causes severe morbidity and mortality, affecting millions of people annually. Of a diverse range of clinical manifestations, local and systemic haemorrhage are of particular relevance, as this may result in ischemia, organ failure and even cardiovascular shock. Thus far, in vitro studies have failed to recapitulate the haemorrhagic effects observed in vivo. Here, we present an organ-on-a-chip approach to investigate the effects of four different snake venoms on a perfused microfluidic blood vessel model. We assess the effect of the venoms of four snake species on epithelial barrier function, cell viability, and contraction/delamination. Our findings reveal two different mechanisms by which the microvasculature is being affected, either by disruption of the endothelial cell membrane or by delamination of the endothelial cell monolayer from its matrix. The use of our blood vessel model may shed light on the key mechanisms by which tissue-damaging venoms exert their effects on the capillary vessels, which could be helpful for the development of effective treatments against snakebites.
Cutaneous wounds are common afflictions that follow a stereotypical healing process involving hemostasis, inflammation, proliferation, and remodeling phases. In the elderly and those suffering from vascular or metabolic diseases, poor healing after cutaneous injuries can lead to open chronic wounds susceptible to infection. The discovery of new therapeutic strategies to improve this defective wound healing requires a better understanding of the cellular behaviors and molecular mechanisms that drive the different phases of wound healing and how these are altered with age or disease. The zebrafish provides an ideal model for visualization and experimental manipulation of the cellular and molecular events during wound healing in the context of an intact, living vertebrate. To facilitate studies of cutaneous wound healing in zebrafish, we have developed an inexpensive, simple, and effective method for generating reproducible cutaneous injuries in adult zebrafish using a rotary tool. We demonstrate that our injury system can be used in combination with high-resolution live imaging to monitor skin re-epithelialization, immune cell recruitment and activation, and vessel regrowth in the same animal over time. This injury system provides a valuable experimental platform to study key cellular and molecular events during wound healing in vivo with unprecedented resolution.
The invention relates to a Chinese medicine preparation, in particular to an ointment for treating cervical spondylosis. The ointment for treating cervical spondylosis is prepared from the following raw materials in parts by weight: 5-8 parts of Chinese caterpillar fungus, 2-4 parts of clematis root, and 1-3 parts of long-noded pit viper. The Chinese caterpillar fungus, the clematis root and the long-noded pit viper are smashed to prepare the ointment. The clematis root is used for dispelling wind, eliminating dampness, and activating meridians to stop pain, the Chinese caterpillar fungus is used for complementing weakness, tonifying qi, and treating aching pain of waist and knee, and the long-noded pit viper is used for dispelling the wind, activating collaterals, and arresting convulsion. The ointment for treating cervical spondylosis can effectively improve the edema and the inflammation of surrounding tissues, rapidly improve symptoms, and accelerate the softening and the absorption of stagnancy. The ointment has functions of expelling wind, removing cold, tonifying spleen, activating collaterals, and promoting blood circulation to arrest pain. The usage and the dosage of the ointment are that people is pasted with one piece of ointment one time, each piece of ointment can be used five days, one curse of treatment adopts three pieces of ointments, and a patient can be cured after one to two curses of treatment. The ointment for treating cervical spondylosis has the advantages that the ointment is less in using the ointment, short in course of treatment, convenient to use, reasonable in efficacy of the ointment, and effective in treatment. Eleven clinical cases of illness prove that the ointment has 63.06% cure rate, 20.72% significant efficiency, 15.32% effective rate and 98.2% total effective rate.
This project will develop and test a comprehensive, web based training system for the artificial pancreas (AP) prototype identified as eDAPT (electronic Diabetes Artificial Pancreas Training). This e-learning training program is to prepare people with diabetes and their physicians on the use of UVA's Artificial Pancreas prototype -- Diabetes Assistant (DiAs), a software platform for the development and outpatient testing of smart phone based systems for Closed Loop Control of diabetes. The e-learning training program will be used in adjunct to in-person training with study staff at the onset of a clinical trial. It will be especially important as the number of clinical sites that use DiAs continue to grow both in the United States and internationally. It is also a critical step in moving the DiAs closer to a commercial product. A validated training program is required to proceed with the Food and Drug Administration (FDA) for both pivotal clinical trials and commercial approval of the AP.
Tele-CGM-monitoring: Subjects are remotely monitored daily through a continuous glucose monitoring (CGM) system (Dexcom G5/6) that communicates via smart phone to a Tidepool designed dashboard. Alerts set for: ≥4 hours without CGM signal, ≥2 hours 54-70 mg/dl, and 15 minutes \<54 mg/dl. Tidepool dashboard automatically emails daily alerts to the Certified Diabetes Educator (CDE). If alerts occurred, the CDE performed telemedicine outreach based on type of alert.
Conventional invasive coronary angiography (CICA) is associated with few but serious complications. It is time consuming for the patient and incur costs to the health institution due to the post-procedure observation needed. Coronary computer tomography angiography (CCTA) is a good alternative to CICA to rule out coronary artery disease (CAD). Moderate to excellent sensitivity and negative predictive values have been reported with 64-slice CT angiography. The main ethical problem has been the radiation doses given to the patient during CT angiography which was high \>10 millisievert(mSv). With 265 or higher slice CT machines and radiation dose reduction techniques, it is possible to evaluate coronary anatomy with radiation doses below 1 mSv. Heart rate reduction with B-blockers is in most cases not necessary with new generation CT machines but is recommended in guidelines.

800 patients already accepted for CICA based on clinical information will be scheduled to undergo CCTA prior to invasive coronary angiography. Coronary anatomy will be described according to American Heart Association (AHA) classification with 17 segment analysis. The main purpose of the study is to achieve high sensitivity and high negative predictive value with CT angiography. Radiation doses in relation to gender and body mass index (BMI) will be monitored. In addition we will measure coronary calcification (Agatson score) and look at any association to the Vitamin D and calcium metabolism. Patient reported quality of life evaluation with validated questionnaires and long term follow up (5 and 10 years) regarding clinical endpoints.
Eligible patients with ER-positive breast cancer will undergo a biopsy and be randomized to receive endocrine therapy (ET) versus endocrine therapy with palbociclib (PET) in a 1:2 ratio. A 1:2 ratio means that twice as many participants will be assigned to the PET arm as compared to the ET arm. After 1 cycle (28 days) another biopsy will be obtained, and both arms will receive avelumab (A) for 3 additional cycles. Patients will then undergo breast surgery.
Subjects will be treated with Granulocyte Colony-Stimulating Factor (G-CSF) for 5 days at a dose of 5 mg/kg twice daily. When count of CD34+ cells is sufficient, the CD34+ cells will be collected by apheresis. Autologous CD34+ cells will be injected into the subjects at a rate of 10 ml/min.
Inspiratory muscles pre-activation (IMPA) has been studied to improve subsequent performance in swimming. However, the effects of IMPA on various parameters in swimmers are still unknown. Therefore, this study aimed to investigate the effects of IMPA on the mechanical parameters, physiological responses, and their possible correlations with swimming performance. A total of 14 young swimmers (aged 16 ± 0 years) underwent a 30-s all-out tethered swimming test, preceded or not by IMPA, a load of 40% of the maximal inspiratory pressure (MIP), and with a volume of 2 sets of 15 repetitions. The mechanical (strength, impulse, and fatigue index) and physiological parameters (skin temperature and lactatemia) and the assessment of perceived exertion and dyspnea were monitored in both protocols. The IMPA used did not increase the swimming force, and skin temperature, decrease blood lactate concentration, or subjective perception of exertion and dyspnea after the high-intensity tethered swimming exercises. Positive correlations were found between mean force and blood lactate (without IMPA: r = 0.62, P = 0.02; with IMPA: r = 0.65, P = 0.01). The impulse was positively correlated with blood lactate (without IMPA: r = 0.71, P < 0.01; with IMPA: r = 0.56, P = 0.03). Our results suggest that new IMPA protocols, possibly with increased volume, should be developed in order to improve the performance of young swimmers.
The control group will receive a new 24G or 22G short peripheral venous catheter with direct view aseptic technique puncture, see blood return and rinse easily with 0.9% sodium chloride solution. The catheter is considered to be in the correct position and can be used normally. Check the condition of the catheter at least 3 times a day, and rinse with 10 ml.9% sodium chloride solution before each intravenous treatment; After disconnection of any infusion, pulse flushing with 0.9% sodium chloride solution 10ml and positive pressure sealing tube flushing to seal the catheter. Collect patient information, including sociodemographic information, duration of intravenous therapy, and details about catheter failure.